At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.


French German Italian Portuguese Russian

Treatment Study for Pediatric Patients with Hemophilia A

Clinical Trial Title: 
A single-arm, multicenter, open-label, phase III clinical trial to evaluate the efficacy, safety and pharmacokinetics of once weekly subcutaneous administration of emicizumab in hemophilia A pediatric patients with inhibitors.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Mindy Simpson, MD
Clinical Trial Protocol Description: 

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of once weekly injections of the study drug in children with hemophilia A and FVIII inhibitors who are currently receiving treatment with FEIBA or NovoSeven drugs. This study will also be evaluating the reduction in the number of bleeds over time while you are receiving the study drug.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a male or female under the age of 18 years old.
  • Have hemophilia A with an inhibitor.
  • Weigh less than 40 kg.
  • Require bypassing agents such as Feiba or NovoSeven.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-3034
Contact Name: 
Mindy Simpson, MD